Nephroprotective Effects of Formononetin in Diabetic Kidney Disease: Mechanistic Insights and Therapeutic Potential

Area of Science:

• Biochemistry
• Pharmacology
• Nephrology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes, characterized by progressive renal fibrosis and dysfunction.
• Formononetin, a natural compound, shows antioxidant and anti-inflammatory effects, but its role in DKD is not fully understood.

Purpose of the Study:

• To investigate the nephroprotective effects and underlying mechanisms of formononetin in DKD.
• To elucidate the antifibrotic actions of formononetin using integrated network pharmacology and RNA sequencing.

Main Methods:

• Utilized in vitro (HK-2 cells) and in vivo (db/db mice) models of DKD.
• Employed network pharmacology and RNA sequencing to identify therapeutic targets and pathways.
• Analyzed key fibrotic markers (TGF-β1, FN, α-SMA) and renal dysfunction indicators (UACR, Scr, BUN, KIM-1, NGAL).

Main Results:

• Formononetin significantly reduced renal fibrosis by suppressing TGF-β1, FN, and α-SMA expression.
• The compound alleviated renal dysfunction markers, including UACR, Scr, BUN, KIM-1, and NGAL.
• Mechanistically, formononetin inhibited the PI3K/AKT/mTOR pathway (reducing inflammation/fibrosis) and activated the p38/MAPK pathway (enhancing autophagy).

Conclusions:

• Formononetin demonstrates significant nephroprotective potential in DKD models.
• Its therapeutic effects are attributed to combined anti-inflammatory and pro-autophagic mechanisms.
• Formononetin is a promising candidate for DKD therapy.